SRPT Sarepta Therapeutics Inc.
139.98
+3.44 (+3%)
Previous Close
136.54
Open
137.5
Price To Book
14.61
Market Cap
9353970888
Shares
66,823,624
Volume
776,270
Short Ratio
Av. Daily Volume
1,063,586
NewsSee all news
- Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019
- 3 Top Biotech Stocks to Buy in February
- Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
- Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)
- Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
SEC filingsSee all SEC filings
- SC 13G - Statement of acquisition of beneficial ownership by individuals
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604166
- 8-K - Current report 19601146
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595125
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19593653
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Casimersen (SRP-4045) - ESSENCE
Duchenne muscular dystrophy
Phase 1/2 updated data released October 3, 2018.
Microdystrophin gene therapy
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy
Phase 1 trial ongoing.
MYO-201
Duchenne muscular dystrophy - LGMD2D
Phase 1/2 complete. Protocol update enabling IV delivery Phase 1/2a trial planned 2018
MYO-102
Duchenne muscular dystrophy - (LGMD2B)
Phase 2/3 initiation of dosing announced February 14, 2019.
LYS-SAF302
Mucopolysaccharidosis type IIIA (MPS IIIA)
Latest News
- Sarepta Therapeutics to Announce Limb-Girdle Muscular Dystrophy Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019
- 3 Top Biotech Stocks to Buy in February
- Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
- Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)
- Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
- Weekly CFO Sells Highlight
- Implied Volatility Surging for Sarepta (SRPT) Stock Options
- See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
- What Solid Biosciences' First Failure Means for Sarepta Therapeutics
- Solid Biosciences shares drop 70% on disappointing Duchenne data
- Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains
- 3 Gene Therapy Stocks With Huge Catalysts in 2019
- Should You Take Comfort From Insider Transactions At Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?
- 6 Biotech Stocks to Watch Now
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fear of Missing Out Is the Main Driving Force in This Market
- Your first trade for Thursday, January 31
- Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sarepta Therapeutics
SEC Filings
- SC 13G - Statement of acquisition of beneficial ownership by individuals
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19604166
- 8-K - Current report 19601146
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595125
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19593653
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19572467
- 8-K - Current report 19512595
- 8-K - Current report 181244716
- 8-K - Current report 181227849
- S-8 - Securities to be offered to employees in employee benefit plans 181224120